Vakula Connect is our regular update for consultants deciding where to take their next assignment and for clients planning their next programme. This edition covers Q3 2024.
Market signals
- FDA issued final guidance on decentralised clinical trials in September; sponsors running hybrid studies needed oversight plans covering local providers and digital health technologies.
- Pharma manufacturing expansion in the US, partly driven by GLP-1 demand, kept validation and quality engineers fully booked.
- Network and infrastructure roles grew as laboratories and plants segmented instrument networks for security.
Roles in demand this quarter
Titles that recurred in client requisitions: Clinical Study Manager (hybrid/DCT), CQV Engineer, Network Security Engineer, Technical Writer (validation). Current openings are always on our careers page.
Signal to leaders
The disciplines that were hardest to fill were the ones where clients needed judgement as well as capacity; briefing for the judgement shortened time-to-fill.
At Vakula
Our trial management team built oversight plans for hybrid studies, and the networking practice delivered its first segmented laboratory network projects.
For consultants
Rate, duration, location and client are disclosed before you decide to interview; you get feedback after every submission; there are no fees to candidates at any stage. Send your resume.
For clients
Send one requisition and judge the shortlist. Start here.
Join the conversation
Tell us what you are working through at info@vakulatech.com; we may feature the question in a future edition.